SCHEMBL22459583

SCHEMBL22459583

COc1ccc(-c2cc(=O)c3c(OC)cc(O)c(-c4cc(-c5cc(=O)c6c(OC)cc(O)cc6o5)ccc4OC)c3o2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.69
▸ MAPT P10636 3/20 0.69
▸ KMT2A Q03164 3/20 0.69
▸ USP2 O75604 2/20 0.69
▸ TP53 P04637 2/20 0.69
▸ KDM4E B2RXH2 1/20 0.69
▸ HPGD P15428 1/20 0.69
▸ ALOX15 P16050 1/20 0.69
▸ HBB P68871 1/20 0.69
▸ HSD17B10 Q99714 1/20 0.69
▸ MMP3 P08254 1/20 0.64
▸ MMP9 P14780 1/20 0.64
▸ POLH Q9Y253 1/20 0.61
▸ APP P05067 6/20 0.61
▸ CYP1B1 Q16678 4/20 0.61
▸ CYP1A1 P04798 3/20 0.61
▸ CYP1A2 P05177 3/20 0.61
▸ IP6K2 Q9UHH9 3/20 0.61
▸ FLT3 P36888 3/20 0.61
▸ KCNA5 P22460 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isoginkgetin SCHEMBL30293900 0.91 MEN1 (0.80) MEN1MAPTKMT2AUSP2TP53
Isoginkgetin SCHEMBL22459983 0.91 MEN1 (0.80) MEN1MAPTKMT2AUSP2TP53
Kayaflavone SCHEMBL27350697 0.89 MEN1 (0.71) MEN1MAPTKMT2AUSP2TP53
Kayaflavone SCHEMBL30646162 0.89 MEN1 (0.71) MEN1MAPTKMT2AUSP2TP53
Sciadopitisin SCHEMBL1158050 0.89 MAPT (0.86) MEN1MAPTKMT2AUSP2TP53
Sciadopitisin SCHEMBL30996894 0.89 MAPT (0.86) MEN1MAPTKMT2AUSP2TP53
SCHEMBL22460005 0.88 MEN1 (0.70) MEN1MAPTKMT2AUSP2TP53
SCHEMBL22459584 0.87 MAPT (0.77) MEN1MAPTKMT2AUSP2TP53
SCHEMBL27350540 0.85 ABCB1 (0.71) MEN1MAPTKMT2AUSP2TP53
SCHEMBL4279323 0.85 ABCB1 (0.80) MEN1MAPTKMT2AUSP2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11110105-B2 Compounds, composition and uses thereof for treating cancer INSTITUT GUSTAVE ROUSSY (FR) 2021-09-07 — — US disclosed
US-20200297741-A1 COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2020-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200297741-A1 COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER PTPRC, PTPRS, PTPRCAP MEN1 2190/4885MAPT 3210/4885KMT2A 3703/4885
US-11110105-B2 Compounds, composition and uses thereof for treating cancer PTPRC, PTPRS, PTPRCAP MEN1 2190/4885MAPT 3210/4885KMT2A 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback